Q1 2026 Market Update: Analyzing THOR’s Proprietary Market Indicators

In our First Quarter 2026 market update, Jim Gore dives deep into THOR Wealth Management’s proprietary market indicators to provide a clear picture of the current investing environment.

By analyzing the THORdex, evaluating fixed income risk measures, and comparing the relative value of stocks versus bonds, we offer a comprehensive look at the underlying data driving the markets today. This objective, data-driven approach allows us to cut through the noise and explain exactly how we are positioning portfolios to manage risk and capture potential opportunities in the months ahead

Charting The Markets Slides:

Line chart of THORideas performance from 1990s to 2010s with blue line fluctuating between low and high values; red line at ~70 and green line around 20. THOR logo below.

THORdex

We kick off the update by looking at the THORdex, our proprietary market indicator.

Currently the indicator has a reading of 70.79 which is telling us that risk is moderately elevated.

Infographic showing a risk spectrum bar from -3 to 3, with red high risk at left, yellow to orange in middle, and green low risk at right; arrows label 'Credit Risk' under the left side and 'Duration Risk' at the right.

Fixed Income Risk Measures

Next we highlight THOR’s fixed income risk indicators. Today they are showing opportunity in duration longer term but moderate signs of risk in credit sensitive bonds.

Semi-circular black gauge labeled BONDS on the left and STOCKS on the right, with a red needle pointing to about -2 on the bonds side; green THOR STOCK VS BOND MEASURE logo in the top-left.

Stock vs Bonds

Long term we see better risk-adjusted opportunity in bonds vs stocks when looking at our stock vs bond indicator.

Navigating Q1 and Beyond

At THOR Wealth Management, utilizing proprietary indicators like the THORdex is a core part of our active investment management strategy. By continuously evaluating fixed income risk and relative asset value, we can make informed, objective decisions for our clients’ portfolios.